Dr.wu Skincare (6523) reported revenue of NT$95.3 million for Oct 2026, +30.0% year on year and +36.1% from the previous month. Revenue for Jan–Oct 2026 was NT$856.9 million (-11.4% year on year).
In Oct 2026, it ranked No. 77 by revenue among 160 Biotech & Medical companies.
Next ex-date: 2026-11-26 (Cash dividend, cash per share NT$4) Taiwan ex-dividend calendar →
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$95.3 million | +30.0% | +36.1% |
| Sep 2026 | NT$70.1 million | -13.4% | -45.8% |
| Aug 2026 | NT$129.3 million | -14.0% | +55.9% |
| Jul 2026 | NT$83 million | -7.2% | -4.7% |
| Jun 2026 | NT$87 million | -6.8% | +58.8% |
| May 2026 | NT$54.8 million | -16.8% | -10.2% |
| Apr 2026 | NT$61.1 million | -8.1% | -23.5% |
| Mar 2026 | NT$79.8 million | -45.6% | -25.2% |
| Feb 2026 | NT$106.7 million | +36.1% | +18.7% |
| Jan 2026 | NT$89.9 million | -26.3% | +2.8% |
| Dec 2025 | NT$87.5 million | +16.9% | -23.3% |
| Nov 2025 | NT$114 million | -18.5% | +55.5% |
| Oct 2025 | NT$73.3 million | -42.6% | -9.3% |
| Sep 2025 | NT$80.9 million | +2.2% | -46.3% |
| Aug 2025 | NT$150.5 million | +16.6% | +68.3% |
| Jul 2025 | NT$89.4 million | -6.9% | -4.2% |
| Jun 2025 | NT$93.3 million | -8.7% | +41.8% |
| May 2025 | NT$65.8 million | -9.1% | -1.0% |
| Apr 2025 | NT$66.5 million | -6.6% | -54.7% |
| Mar 2025 | NT$146.7 million | +4.5% | +87.2% |
| Feb 2025 | NT$78.4 million | -15.7% | -35.7% |
| Jan 2025 | NT$121.9 million | +5.2% | +63.0% |
| Dec 2024 | NT$74.8 million | -24.6% | -46.5% |
| Nov 2024 | NT$139.9 million | +5.0% | +9.5% |
| Oct 2024 | NT$127.8 million | +33.9% | +61.5% |
Jan–Oct 2026 cumulative: NT$856.9 million (-11.4% YoY)
Other Biotech & Medical companies
Compare with peers: Dr.wu Skincare vs PEC / Dr.wu Skincare vs Lotus Pharm / Dr.wu Skincare vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16